Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency

被引：14
|
作者：
Focosi, D. [1 ]
Franchini, M. [2 ]
机构：
[1] Pisa Univ Hosp, North Western Tuscany Blood Bank, Via Paradisa 2, I-56124 Pisa, Italy
[2] Carlo Poma Hosp, Dept Hematol & Transfus Med, Mantua, Italy
来源：
TRANSFUSION CLINIQUE ET BIOLOGIQUE | 2021年 / 28卷 / 02期
关键词：
Pathogen inactivation; Pathogen reduction technologies; COVID-19 convalescent plasma; Neutralizing antibodies; Efficacy; IgG subclasses; FRESH-FROZEN PLASMA; ULTRAVIOLET-LIGHT; AMOTOSALEN; RIBOFLAVIN; INACTIVATION;
D O I：
10.1016/j.tracli.2021.02.005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Pathogen reduction technologies (PRT) have been recommended by many regulatory authorities to minimize the residual risk of transfusion-transmitted infections associated with COVID19 convalescent plasma. While its impact on safety and its cost-effectiveness are nowadays well proven, there is theoretical concern that PRT could impact efficacy of convalescent plasma by altering concentration and/or function of the neutralizing antibodies (nAb). We review here the evidence supporting a lack of significant detrimental effect from PRTs on nAbs. (C) 2021 Societe francaise de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：132 / 134
页数：3
相关论文
共 50 条
  • [31] Convalescent plasma therapy in patients with COVID-19
    Altuntas, Fevzi
    Ata, Naim
    Yigenoglu, Tugce Nur
    Basci, Semih
    Dal, Mehmet Sinan
    Korkmaz, Serdal
    Namdaroglu, Sinem
    Basturk, Abdulkadir
    Hacibekiroglu, Tuba
    Dogu, Mehmet Hilmi
    Berber, Ilhami
    Dal, Kursat
    Kinik, Kerem
    Haznedaroglu, Ibrahim
    Yilmaz, Fatma Meric
    Kilic, Isa
    Demircioglu, Sinan
    Yosunkaya, Alper
    Erkurt, Mehmet Ali
    Turgut, Burhan
    Caglayan, Murat
    Celik, Osman
    [J]. TRANSFUSION AND APHERESIS SCIENCE, 2021, 60 (01) : 102955
  • [32] COVID-19 convalescent plasma: phase 2
    Knudson, C. Michael
    Jackson, J. Brooks
    [J]. TRANSFUSION, 2020, 60 (06) : 1332 - 1333
  • [33] Use of convalescent plasma in the treatment of COVID-19
    Michael J. Joyner
    Nigel Paneth
    Arturo Casadevall
    [J]. Nature Reviews Nephrology, 2023, 19 : 271 - 271
  • [34] Convalescent Plasma for the Treatment of Severe COVID-19
    Franchini, Massimo
    Liumbruno, Giancarlo Maria
    [J]. BIOLOGICS-TARGETS & THERAPY, 2021, 15 : 31 - 38
  • [35] Convalescent Plasma: Promise for COVID-19 Pandemic
    Sheikh, Sadaf
    Baig, Muhammad Akbar
    [J]. JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2020, 30 (06): : S87 - S87
  • [36] Donating convalescent plasma for COVID-19 patients
    Emily Black
    [J]. British Dental Journal, 2020, 229 : 643 - 643
  • [37] Convalescent plasma in the management of COVID-19 pneumonia
    Elbadawi, Ayman
    Shnoda, Mina
    Laguio-Vila, Maryrose
    Mamas, Mamas A.
    Elgendy, Islam Y.
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2021, 89 : 121 - 123
  • [38] Convalescent (Immune) Plasma Therapy and COVID-19
    Wiwanitkit, Viroj
    [J]. ERCIYES MEDICAL JOURNAL, 2020, 42 (04) : 493 - 493
  • [39] Screening donors for COVID-19 convalescent plasma
    Wang, Henry E.
    Ostrosky-Zeichner, Luis
    Katz, Jeffrey
    Wanger, Audrey
    Bai, Yu
    Sridhar, Sujatha
    Patel, Bela
    [J]. TRANSFUSION, 2021, 61 (04) : 1047 - 1052
  • [40] How Safe Is COVID-19 Convalescent Plasma?
    Franchini, Massimo
    Cruciani, Mario
    [J]. MAYO CLINIC PROCEEDINGS, 2021, 96 (08) : 2279 - +
12345